SMMT Summit Therapeutics Загрузка... : Бычьи и медвежьи мнения аналитиков
Загрузка графика...
Лучшие сигналы
Лента
14:00
04 авг
04 авг
Comparisons to ivonescimab, which is partnered by Summit, implicitly benchmark Pfizer's drug against Summit's key asset.
Выс.
23:56
03 авг
03 авг
Summit Therapeutics speculative biotech with insider buying.
Summit Therapeutics has heavy insider buying ($50M by co-CEO, $5M by management), is awaiting FDA approval with trial results better than an existing drug, and can be treated as a speculative buy for risk-tolerant investors.
Низ.
11:56
01 июн
01 июн
Pre-market movers report highlights Nvidia and Microsoft unveiling AI superchip for PCs.
Pre-market movers report highlights Nvidia and Microsoft unveiling AI superchip for PCs, causing chip competitors to fall and partners to gain, along with other corporate news including Berkshire Hathaway's acquisition of TMHC and FedEx completing its spin-off.
Об аналитическом покрытии SMMT
Buzzberg отслеживает SMMT (Summit Therapeutics) в 3 источниках. Бычьих сигналов: 1, медвежьих: 0, от 3 аналитиков. Сентимент преимущественно бычий (33%). Всего отслеживаются 3 торговые идеи. За последние 7 дней: бычьих: 1, наблюдение: 1. Последние спикеры: Chris Boshoff, Jim Cramer, Newsquawk.